Skip to content
HowShorted

Karyopharm Therapeutics Inc. short interest in 2018

In 2018, Karyopharm Therapeutics Inc.'s disclosed short interest ran from 4.10% of shares outstanding on 12 Jan 2018 to 10.01% on 31 Dec 2018, a change of +5.91 percentage points. The year's high was 11.19% on 15 Nov 2018 and its low 4.05% on 31 Jan 2018, averaging 7.96% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.98 days on 13 Jul 2018. Full history: Karyopharm Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Karyopharm Therapeutics Inc. in 2018

2018 in figures

Start of year
4.10% (12 Jan 2018)
End of year
10.01% (31 Dec 2018)
Change
+5.91 pp
High
11.19% (15 Nov 2018)
Low
4.05% (31 Jan 2018)
Average
7.96%
Highest days to cover
17.98 (13 Jul 2018)
SEC filings marked
9

Every report in 2018

Karyopharm Therapeutics Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20184.10%10.42
31 Jan 20184.05%9.64
15 Feb 20184.33%5.70
28 Feb 20184.47%8.85
15 Mar 20184.19%4.0010-K filed, results (8-K)
29 Mar 20184.75%4.61
13 Apr 20185.19%3.64
30 Apr 20187.16%4.83
15 May 20188.01%2.10results (8-K), 10-Q filed, results (8-K)
31 May 20187.38%5.94
15 Jun 20189.09%5.77
29 Jun 201810.93%6.26
13 Jul 201810.82%17.98
31 Jul 201810.32%13.78
15 Aug 20188.17%13.5710-Q filed, results (8-K)
31 Aug 20188.41%11.15
14 Sep 20188.29%10.48
28 Sep 20188.29%7.60
15 Oct 201811.10%4.13
31 Oct 201810.51%8.83
15 Nov 201811.19%11.7610-Q filed, results (8-K)
30 Nov 201811.06%12.69
14 Dec 20189.16%7.70
31 Dec 201810.01%8.24

See also: Karyopharm Therapeutics Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.